Introduction
============

Parkinson disease (PD) is a progressive neurodegenerative disorder with widely heterogeneous manifestations, including motor, nonmotor and neuropsychiatric symptoms. It affect\~1% of the people older than 60 years.[@b1-ndt-13-329]--[@b3-ndt-13-329] The major pathologic feature of PD is the loss of dopaminergic neurons in substantia nigra pars compacta and, consequently, basal ganglia.[@b4-ndt-13-329],[@b5-ndt-13-329]

Sex differences in prevalence, clinical presentations and severity of PD have been reported in some previous studies.[@b6-ndt-13-329]--[@b9-ndt-13-329] Although the exact sources of these differences in PD are unknown, sex hormones, genetic factors and variations in dopaminergic pathways have been proposed as possible underlying reasons.[@b10-ndt-13-329]--[@b14-ndt-13-329] Identifying sexual variations influences prevention, therapeutic strategies and understanding of sex-related neurobiological differences.[@b15-ndt-13-329],[@b16-ndt-13-329] Exploration of sexual dimorphism in neurologic diseases such as PD has been recently announced as a research need.[@b3-ndt-13-329] While studies are unanimous about the higher prevalence of PD among men, there are conflicting data regarding sex differences in clinical manifestations, progression and treatment outcome.[@b17-ndt-13-329]--[@b23-ndt-13-329] Motor presentations (ie, tremor and dyskinesia), psychological manifestations (especially depression), sleep behavior disorders and cognitive impairment have been reported as potential aspects of sexual dimorphism in PD.[@b17-ndt-13-329]--[@b23-ndt-13-329] However, data are still controversial, inconclusive and even conflicting in some aspects. As an example, a recent randomized clinical trial did not find any sex differences in daily activities and main motor features.[@b24-ndt-13-329] In addition to lack of comprehensive data, these controversies can be partly due to interrelationship and confounding effects of clinical and demographic variables.[@b3-ndt-13-329] Some clinical features that were previously reported to be sex related failed to show any difference between males and females with PD when controlled for other demographic and clinical variables. For instance, cognitive impairment was reported to be more common in men;[@b9-ndt-13-329] however, the difference was much less pronounced when the effect of age, level of education and disease severity were taken into account.[@b23-ndt-13-329] In another large study, univariate analysis showed that daily activity was more impaired in females, but multivariate analysis revealed no significant sex difference.[@b24-ndt-13-329]

Having collected comprehensive data on different PD- related and general features, we aimed to further investigate sexual dimorphism in PD. Our objective was to determine independent differences in clinical manifestations and subtypes, psychosocial functioning, quality of life (QoL) and its domains between males and females with idiopathic Parkinson's disease (IPD) using a powerful statistical approach. Our a priori research hypothesis was that females with PD experienced more severe nonmotor manifestations, which would also influence their QoL and psychosocial functioning more prominently than males.

Patients and methods
====================

Study setting
-------------

This study was conducted on 157 consecutive patients with IPD from an outpatient referral movement disorders clinic in Tehran, Iran, between October 2011 and December 2012. This was a collaborative project between Iran University of Medical Sciences (Tehran, Iran) and Karolinska Institute (Stockholm, Sweden).

Ethics
------

The study protocol was approved by the ethics committee of the Neurology Department at Firoozgar Clinical Research Development Center (FCRDC; affiliated to Iran University of Medical Sciences). Data were stored and treated according to the ethical guidelines of biomedical research. Prior to the launch of the study, all patients were informed about the aims and procedures. All participants provided their verbal informed consent to participate in this study. Since the project was designed as an observational research, verbal form of consent was approved by the aforementioned ethics committee. Participation in this study was voluntary, and the patients were free to withdraw from the project whenever they decided. Furthermore, the identity of research participants was protected, since the data files were anonymous and all names were omitted.

Patients' requirement
---------------------

Recruited patients fulfilled the following inclusion criteria: diagnosis of IPD based on the UK brain bank criteria,[@b25-ndt-13-329] which was assessed by the same neurologist who was specialized in movement disorders for all participants; current age of 30 years or older and motor disability in the mild-to-severe range but not in the advanced stages that needs wheelchair or hospitalization according to the Hoehn and Yahr (H&Y) criteria (stage \<5).[@b26-ndt-13-329] Patients with moderate to severe dementia were excluded from the study, as were those with atypical Parkinsonism, including multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and vascular or drug-induced Parkinsonism.

Assessments
-----------

Data collection was performed through face-to-face interviews with eligible patients by a trained group of medical interns by means of validated questionnaires and checklists. Patients were also examined for clinical assessments and diagnosis by one neurologist specialized in movement disorders. The demographic checklist consisted of baseline variables (age and sex), educational status, history of smoking, comorbidities, duration of PD (time passed from diagnosis) and history of levodopa administration. Total comorbidity burden was calculated by summing up the number of chronic comorbid conditions in each participant, including depression, hypertension, interstitial heart disease (IHD), diabetes, stroke/transient ischemic attack (TIA) and osteoporosis. Data were collected based on participants' self-reports and their medical records at the referral center. Clinical characteristics of PD were assessed using the following scales and/or definitions: Motor severity: Unified Parkinson's Disease Rating Scale (UPDRS) subscales I--IV, dyskinesia score (sum of UPDRS -- Part IV items 32--34), fluctuation score (sum of UPDRS -- Part IV items 36--39), H&Y staging and Schwab and England activities of daily living (ADL);Motor subtypes: postural instability--gait difficulty (PIGD) score (sum of UPDRS -- Part III items concerning rise, gait and postural instability) and freezing--speech--swallowing (FOSS) score (sum of UPDRS -- Part II items on freezing, speech and swallowing);Predominance of core manifestations: proportion of UPDRS -- Part III on motor scores accounted for tremor (items 20--21), rigidity (item 22), bradykinesia (items 23--26 and 31) and gait (items 27--30) in percentage;Asymmetry Index: absolute differences in UPDRS between sides divided by the total UPDRS -- Part III items 20--26;Axial/limb ratio: sum of UPDRS -- Part III items 18, 19, 22 and 27--30 divided by the sum of UPDRS -- Part III items 20--26;Other motor symptoms: presence of falls and freezing andNonmotor manifestations: the Hospital Anxiety and Depression Scale (HADS) questionnaire to measure anxiety and depression,[@b27-ndt-13-329] Fatigue Severity Scale (FSS) to investigate fatigue,[@b28-ndt-13-329] the Mini-Nutritional Assessment (MNA) questionnaire together with anthropometric measurements for nutritional status,[@b29-ndt-13-329] Persian-translated and validated version of the Scales for Outcomes in Parkinson's Disease -- Psychosocial (SCOPA-PS) questionnaire[@b30-ndt-13-329] to assess psychosocial functioning and validated Persian version of the 39-item PD Questionnaire (PDQ-39)[@b31-ndt-13-329] to evaluate health-related quality of life (HRQoL). All clinical assessments were done when the patients were in the "on" state.

Statistical analysis
--------------------

Statistical descriptions and univariate and multivariate regression analyses were performed using the IBM SPSS Statistics for Windows, version 23 (IBM Corporation, Armonk, NY, USA). Mean (standard deviation \[SD\]) and frequency percentages were used to describe numerical and categorical variables, respectively. Kolmogorov--Smirnov test was applied to check the normality assumption for continuous variables. Since the normality of distribution was met, we used parametric tests for between-group comparisons. Univariate comparisons between males and females were performed using either independent samples *t*-test, chi-square test or Fisher's exact test where appropriate. We used multivariate linear regression model to adjust the between-group differences in some numeric variables of interest for the baseline differences in disease duration and level of education. A two-tailed *P*-value of \<0.05 was considered as the threshold to show statistical significant differences.

In order to evaluate the strength of each variable to discriminate male and female patients with PD, we applied Orthogonal Partial Least Squares -- Discriminant Analysis (OPLS-DA) method using SIMCA software, version 14.1 (MKS Umetrics AB, Umeå, Sweden). Unit variance (UV) scaling was used to transform crude data prior to the OPLS-DA modeling. The OPLS-DA method divides the systematic variation in the *X*-block consisting of a comprehensive list of demographic and PD-related features to separate males and females with PD into two model parts. One part models the co-variation between X and Y, and another part expresses the *X*-variation that is not related to Y and is shown by the orthogonal component(s). This method results in a better class resolution for a discriminant problem such as the case in our study. Furthermore, the OPLS-DA method made it possible to compare the strength of different variables with various measurement units and scales to discriminate males and females with PD by means of values of standardized loading, their standard error (SE) and 95% confidence interval (CI). We visualized findings from the OPLS-DA method by three different plots with the following parameters: Score scatter plot: to show the performance of the entire OPLS-DA model to separate males and females where *t*1 refers to the score of each participant from the main discriminant component in the *X*-block (horizontal axis), while *t*2 shows the score of each participant from the *Y*-orthogonal component (vertical axis);Loadings bars: this is a one-dimensional plot representing loading value (*p*1) of each feature to discriminate males and females based on the main discriminant component of the OPLS-DA model;Loadings scatter plot: in this plot, *p*1 refers to the loading values of each feature from the main discriminant component to discriminate males and females (horizontal axis) and *p*2 represents the loadings of each variable from the *Y*-orthogonal component for the differences between features that are not related to sex (vertical axis).

Results
=======

Overall, 157 individuals consisting of 108 males and 49 females with PD were recruited in our study. [Table 1](#t1-ndt-13-329){ref-type="table"} summarizes the results for univariate comparison of the demography, motor severity and medications, motor subtypes, nonmotor features and QoL indicators between the two subgroups.

Univariate and multivariate comparisons
---------------------------------------

The age at PD onset did not significantly differ between males and females (55.2 \[SD =11.6\] year vs 53.4 \[SD =12.4\] year, *P*=0.384), however, disease duration was longer in females at the time of recruitment (6.1 \[SD =4.9\] year vs 8.2 \[SD =5.7\] year, *P*=0.023). PD-related medication profile did not differ between males and females. Univariate differences in motor features such as total UPDRS and freezing score disappeared after adjustment for baseline difference. Among nonmotor features, anxiety, depression, fatigue and psychosocial functioning were all significantly more severe in female PD patients ([Table 1](#t1-ndt-13-329){ref-type="table"}). After statistical adjustment for the baseline differences in disease duration and level of education, female individuals still showed significantly higher score in anxiety (mean difference =2.2 \[95% CI: 0.5--4.0\], *P*=0.011) and borderline higher score in depression (mean difference =1.3 \[95% CI: −0.2--2.7\], *P*=0.079). Furthermore, female PD patients had significantly worse nutritional status and higher Parkinson's Disease Summary Index (PDSI), both of which remained statistically significant after multivariate adjustment (mean difference for MNA score =−1.5 \[95% CI: −2.5 to −0.4\], *P*=0.009; mean difference for PDSI score =6.9 \[95% CI: 1.9--11.8\], *P*=0.006).

Among different domains of QoL, females were significantly worse in mobility (40.8 \[SD =27.4\] vs 22.5 \[SD =24.0\], *P*\<0.001), emotional well-being (39.4 \[SD =24.4\] vs 23.5 \[SD =21.7\], *P*\<0.001), social support (20.1 \[SD =25.9\] vs 7.5 \[SD =15.9\], *P*\<0.001) and bodily discomfort (33.0 \[SD =25.3\] vs 17.2 \[SD =20.1\], *P*\<0.001). All of these differences were still significant even after multivariate adjustment for the baseline differences in disease duration and level of education between males and females, resulting in the mean difference of 11.9 (95% CI: 3.5--20.3, *P*=0.006) in mobility, 12.5 (95% CI: 4.7--20.3, *P*=0.002) in emotional well-being and 11.0 (95% CI: 0.9--21.5, *P*=0.001) and 14.2 (95% CI: 6.4--21.9, *P*\<0.001) in bodily discomfort domain of QoL.

Discriminant analysis
---------------------

The OPLS-DA model that fitted the best to our dataset had the overall cross-validated predictive *R*^2^ value of 0.33. The score scatter plot in [Figure 1](#f1-ndt-13-329){ref-type="fig"} shows the performance of this model to discriminate males and females with PD. The corresponding loading value of each variable in the OPLS-DA model and its 95% CI are shown in [Figure 2](#f2-ndt-13-329){ref-type="fig"}, and the loadings scatter plot is illustrated in [Figure 3](#f3-ndt-13-329){ref-type="fig"}. Based on the absolute loading value for each variable in the OPLS-DA model, emotional well-being (mean =−0.22, SE =0.14), bodily discomfort (mean =−0.18, SE =0.13), social support (mean =−0.17, SE =0.19), mobility (mean =−0.17, SE =0.04) and communication (mean =−0.12, SE =0.15) domains of QoL, together with anxiety (mean =−0.18, SE =0.10), depression (mean =−0.17, SE =0.08) and psychosocial functioning (mean =−0.16, SE =0.11), were the strongest features with higher values in favor of females to discriminate the two sexes in PD population ([Figures 2](#f2-ndt-13-329){ref-type="fig"} and [3](#f3-ndt-13-329){ref-type="fig"}). Nutritional status (mean =0.13, SE =0.07), Schwab and England ADL score (mean =0.06, SE =0.13), and orthostasis (mean =0.06, SE =0.05) were also found to be strong discriminators in the model, nevertheless, with higher values in favor of the male PD patients.

Discussion
==========

Our study is one of the few attempts to comprehensively investigate sexual dimorphism in PD. We applied powerful multivariate statistical methods to explore independent sex differences in clinical manifestations, HRQoL and psychosocial functioning of people with PD. In general, females with PD were significantly worse in psychological features such as anxiety and depression, nutritional status and specific domains of QoL, namely, mobility, emotional well-being, social support and bodily discomfort. Neuropsychiatric symptoms are among the main manifestations of sexual dimorphism in PD. Studies have suggested that emotional symptoms of PD, especially depression, are more common and more severe in females than in males.[@b32-ndt-13-329]--[@b34-ndt-13-329] However, these findings were not approved by a large prospective study, which found no difference in the prevalence or severity of depression evaluated by Beck Depression Inventory (BDI) between females and males.[@b24-ndt-13-329] In our study, females with PD tended to be more affected from psychological symptoms. We found that the scores for anxiety, psychosocial functioning and emotional well-being were all higher among females demonstrating a worse status. Conflicting results can be, in part, explained by ethnic, cultural and environmental differences as well as the use of different depression scales. In some cultures and environments, women are more prone to be stigmatized by disabling conditions,[@b35-ndt-13-329],[@b36-ndt-13-329] which make them more vulnerable to emotional and psychosocial adverse effects of PD.

Social and physical well-being, measured separately or as parts of QoL questionnaires, are important contributors of patient's QoL.[@b37-ndt-13-329],[@b38-ndt-13-329] In our study, physical discomfort, including mobility, fatigue and bodily discomfort, was more severe among female participants. This finding is confirmed by previous studies of PD populations,[@b17-ndt-13-329],[@b34-ndt-13-329],[@b39-ndt-13-329] as well as those of general population showing more severe physical discomfort in healthy older women compared to males of the same age group.[@b40-ndt-13-329]--[@b42-ndt-13-329] Our results showed that despite the lack of statistically significant difference in social stigma, females displayed worse communication and psychosocial functioning. These sex-related differences can be the consequences of more severe emotional disturbance, physical discomfort, and poorer social supports in females compared to males with PD.

In our study, self-reported cognitive impairment was higher in female participants based on the cognition dimension of PDQ-39. In contrast, some studies have suggested that cognitive decline in PD is more severe among males.[@b18-ndt-13-329],[@b23-ndt-13-329] Nonetheless, as different dimensions of cognitive performance have been shown to be sex related in healthy elderly adults (for instance, males have better visuospatial ability, while females perform better on face and verbal recognition and semantic fluency tests[@b43-ndt-13-329]--[@b45-ndt-13-329]), different dimensions of cognitive performance must be investigated in order to clarify sexual dimorphism of cognition in PD.

Studies have reported several sex differences in motor symptoms of PD. Tremor and dyskinesia are reported to occur more frequently in females,[@b8-ndt-13-329],[@b18-ndt-13-329],[@b33-ndt-13-329] whereas gait disturbance is more common in males.[@b19-ndt-13-329] However, in line to one prospective study that had also adjusted the differences for the confounding effects of demographics and clinical covariates,[@b24-ndt-13-329] we also could not find sex-related differences in motor symptoms.

Sleep quality is the other symptom of PD, which is believed to be sex related, but still remained a controversial issue. Rapid eye movement (REM) sleep behavior disorder (RBD) was reported as a male-related symptom in PD;[@b33-ndt-13-329],[@b46-ndt-13-329]--[@b48-ndt-13-329] some other sleep disturbances were found to be more severe among females.[@b34-ndt-13-329],[@b49-ndt-13-329] We did not find any difference in sleep disturbance between males and females using the nonmotor items of the UPDRS. A more thorough assessment with a valid and specific tool such as polysomnography is required to investigate sexual dimorphism in sleep disorders in people with PD.

The comprehensive list of PD-related features and general aspects of daily life is the most important strength of our study. Previous studies have investigated sexual dimorphism in manifestations of PD with rather small sample size not being controlled for the potential confounders.[@b3-ndt-13-329],[@b50-ndt-13-329] In our study, we evaluated a large list of variables (some of which were considered for sexual dimorphism in PD for the first time) and applied a strong multivariate statistical approach, OPLS-DA, to take into account all potential confounding interactions. Nevertheless, we also acknowledge our limitations. This study was designed as a cross-sectional research that restricts any causal inferences and going beyond associations. There are other aspects of sexual dimorphism in PD that need to be addressed in future research, namely, course of progression and mortality. There is a potential risk for selection bias since all recruited patients were from an outpatient neurology clinic where the majority of patients had mild-to-moderate IPD. As a result, our findings may not be generalized to all people with PD, particularly those with end-stage disease. Considering time restriction for data collection spent in each participant, we ought to rely on the items from UPDRS for some variables, which might not be sensitive enough to show between-group differences on this summary scale. Therefore, more sensitive gold-standard tools might potentially show different results for such features. Our rather small sample size in comparison with few large previous studies should also be noted. Augustine et al[@b24-ndt-13-329] reported that studies with smaller sample sizes were more likely to report sex differences in different clinical features. We should also add the uneven number of males and females in our study as another limitation; however, it could be expected for PD that affects men more frequently.[@b51-ndt-13-329] Yet the comprehensive list of variables and appropriate multivariate statistical methods of the present study overcame these issues and strengthened our findings.

Conclusion
==========

This study provides a comprehensive understanding of sexual dimorphism in different motor and nonmotor features of PD and various domains of daily life by using sophisticated statistical analysis to evaluate the independent differences between males and females. After controlling for potential confounders, anxiety, depression, mobility, emotional well-being, social support, bodily discomfort and psychosocial functioning were significantly worse in female individuals with PD. On the other hand, male PD patients had better nutritional status (though with rather small effect size for difference) and ADL but also more severe orthostasis. Conclusively, there are considerable differences in psychiatric nonmotor manifestations. Concordance of depression, anxiety and overall psychosocial burden in being more severe in women is in favor of the presence of a considerable sex dimorphism in neuropsychiatric symptoms, which in turn suggest its clinical importance. QoL and psychosocial consequences of PD between males and females should be addressed for developing a more personalized caring approach. These aspects of sexual dimorphism in PD also enlighten the features that are more likely to be affected in each sex and should be specifically targeted when managing male and female individuals with PD. As for clinical implication, clinicians should consider sex differences in the evaluation and management of patients with PD. For example, they should be aware of the higher risk of psychological manifestations in women and therefore should screen them accurately in a timely manner and, if necessary, refer them to a psychologist in the early stages of these manifestations. Sex-specific symptoms highlight the importance of sex-specific treatments; hence, future studies should investigate the effects of specific interventions for females. Moreover, educational interventions are also needed in order to improve social support for women with PD and reduce their extra psychosocial burden.
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![Score scatter plot to show the performance of the OPLS model to separate male and female PD patients.\
**Note:** The separation of the two classes of observations are shown in the horizontal (*t*1) direction, while the vertical (*t*2) direction expresses within-class variability.\
**Abbreviations:** OPLS, Orthogonal Partial Least Squares; PD, Parkinson's disease; *t*1, score of each participant from the main discriminant component in the *X*-block (horizontal axis); *t*2, score of each participant from the *Y*-orthogonal component (vertical axis).](ndt-13-329Fig1){#f1-ndt-13-329}

![Loading plots of the OPLS model to separate male and female PD patients showing the importance of each feature for this discrimination.\
**Abbreviations:** OPLS, Orthogonal Partial Least Squares; PD, Parkinson's disease; *p*1, loading value; PDQ, PD questionnaire; SCOPA, Scales for Outcomes in Parkinson's Disease; CV, cardiovascular; FOSS, freezing--speech--swallowing; UPDRS, Unified Parkinson's Disease Rating Scale; ADL, activities of daily living; PIGD, postural instability--gait difficulty; MNA, Mini-Nutritional Assessment.](ndt-13-329Fig2){#f2-ndt-13-329}

![Loadings scatter plot *p*1 vs *p*2 to show the performance each feature/characteristic of the OPLS model to separate male and female PD patients.\
**Notes:** The horizontal axis displays the *X*-loadings *p* and the *Y*-loadings *q* of the predictive component. The vertical axis displays the *X*-loadings *p*(o) and the *Y*-loadings *s*(o) for the *Y*-orthogonal component. *X*-variables situated in the vicinity of the dummy *Y*-variables have the highest discriminatory power between the classes.\
**Abbreviations:** OPLS, Orthogonal Partial Least Squares; PD, Parkinson's disease; PDQ, PD questionnaire; SCOPA, Scales for Outcomes in Parkinson's Disease; ADL, activities of daily living; CV, cardiovascular; FOSS, freezing--speech--swallowing; UPDRS, Unified Parkinson's Disease Rating Scale; PIGD, postural instability--gait difficulty; MNA, Mini-Nutritional Assessment.](ndt-13-329Fig3){#f3-ndt-13-329}

###### 

Comparison of demographic characteristics, disease severity scales, psychiatric features, nutritional status and QoL scores between males and females with PD

  Characteristics                                                                 Male (n=108)    Female (n=49)   *P*-value
  ------------------------------------------------------------------------------- --------------- --------------- -------------
  **Demography and general information**                                                                          
  Age (year), mean (SD)                                                                                           
   Current                                                                        61.4 (11.2)     60.5 (13.6)     0.685
   PD onset                                                                       55.2 (11.6)     53.4 (12.4)     0.384
  Duration of disease (year), mean (SD)                                           6.1 (4.9)       8.2 (5.7)       **0.023**
  Level of education, n (%)                                                                                       **0.015**
   Illiterate                                                                     7 (6.5)         10 (21.3)       
   Primary and/or secondary                                                       26 (24.1)       11 (23.4)       
   High school/diploma                                                            28 (25.9)       15 (31.9)       
   College and/or university                                                      47 (43.5)       11 (23.4)       
  Smoking, n (%)                                                                  15 (13.9)       2 (4.1)         0.095
  Comorbidities, n (%)                                                                                            
   Depression                                                                     18 (16.8)       19 (40.4)       **0.002**
   Hypertension                                                                   16 (15.0)       12 (25.0)       0.133
   IHD                                                                            19 (17.8)       5 (10.9)        0.283
   Diabetes                                                                       10 (9.3)        10 (21.7)       **0.037**
   Stroke/TIA                                                                     1 (0.9)         0               1
   Osteoporosis                                                                   8 (7.5)         11 (23.9)       **0.005**
   Total (comorbidity burden), mean (SD)                                          0.5 (1.0)       0.8 (1.0)       
  **Motor severity and medications**                                                                              
  UPDRS score, mean (SD)                                                                                          
   Part II -- ADL                                                                 11.4 (7.4)      12.3 (7.4)      0.471
   Part III -- motor                                                              15.0 (9.0)      16.8 (9.4)      0.251
   Part IV -- complications                                                                                       
   Dyskinesia                                                                     0.9 (1.5)       0.9 (1.9)       0.961
   Wearing off                                                                    1.7 (1.3)       1.6 (1.3)       0.698
   Total                                                                          31.2 (17.6)     34.6 (19.3)     0.322
  H&Y stage, mean (SD)                                                            1.9 (0.9)       2.2 (0.9)       **0.035**
  Schwab and England ADL score (%), mean (SD)                                     82.2 (17.2)     76.7 (19.3)     0.076
  Motor impairment score A,[a](#tfn1-ndt-13-329){ref-type="table-fn"} mean (SD)   11.2 (6.3)      12.1 (6.4)      0.387
  Motor impairment score B,[b](#tfn2-ndt-13-329){ref-type="table-fn"} mean (SD)   3.7 (3.5)       4.7 (3.7)       0.132
  Medications                                                                                                     
   Levodopa dose (mg), mean (SD)                                                                                  
   Cumulative daily dose (mg)                                                     869.0 (468.0)   855.4 (406.3)   0.866
   Weight-adjusted daily dose (mg/kg)                                             12.1 (6.8)      13.6 (8.1)      0.231
   Dopamine agonists, n (%)                                                       58 (54.7)       25 (56.8)       0.814
   Amantadine, n (%)                                                              48 (45.7)       22 (46.8)       0.900
   Selegiline, n (%)                                                              10 (9.5)        8 (18.6)        0.125
   Antidepressants, n (%)                                                         18 (16.7)       12 (24.5)       0.248
   Antihypertensive, n (%)                                                        1 (0.9)         0               1
  Progression rate,[c](#tfn3-ndt-13-329){ref-type="table-fn"} mean (SD)           7.2 (5.7)       6.2 (4.9)       0.368
  **Motor subtypes**                                                                                              
  Tremor -- % of UPDRS -- Part III, mean (SD)                                     15.6 (13.7)     13.3 (13.6)     0.344
  Rigidity -- % of UPDRS -- Part III, mean (SD)                                   10.5 (7.3)      9.5 (6.9)       0.392
  Bradykinesia -- % of UPDRS -- Part III, mean (SD)                               40.3 (17.2)     43.4 (17.5)     0.317
  Gait -- % of UPDRS -- Part III, mean (SD)                                       16.4 (12.1)     20.2 (12.2)     0.071
  Freezing, mean (SD)                                                             0.4 (0.8)       0.8 (1.0)       **0.027**
  Falls, mean (SD)                                                                0.6 (1.1)       0.9 (1.0)       0.216
  Axial/limb ratio, mean (SD)                                                     0.9 (0.8)       0.9 (0.5)       0.738
  Asymmetry Index, mean (SD)                                                      0.2 (0.2)       0.1 (0.2)       0.160
  PIGD score, mean (SD)                                                           2.1 (2.3)       2.9 (2.5)       0.050
  FOSS score, mean (SD)                                                           1.6 (1.7)       2.0 (1.7)       0.202
  **Nonmotor features**                                                                                           
  UPDRS score, Part I -- mental, mean (SD)                                        1.9 (2.0)       2.7 (3.1)       0.098
  Cognitive impairment, mean (SD)                                                 0.3 (0.5)       0.5 (0.9)       0.244
  Hallucination, mean (SD)                                                        0.3 (0.7)       0.3 (0.9)       0.953
  Apathy, mean (SD)                                                               0.6 (1.1)       0.9 (1.2)       0.255
  Sleep disturbances, n (%)                                                       38 (35.2)       20 (40.8)       0.498
  Orthostasis, n (%)                                                              23 (21.3)       5 (10.2)        0.093
  Anxiety score (HADS), mean (SD)                                                 5.9 (4.9)       8.7 (5.1)       **0.002**
  Depression score (HADS), mean (SD)                                              4.4 (4.2)       6.6 (4.4)       **0.003**
  Fatigue score (FSS), mean (SD)                                                  4.3 (2.0)       5.0 (1.6)       **0.012**
  Nutritional status score (MNA), mean (SD)                                       25.8 (2.6)      23.8 (4.2)      **0.003**
  Psychosocial functioning score (SCOPA-PS, %), mean (SD)                         23.1 (23.1)     32.1 (19.1)     **0.018**
  QoL (PDQ-39), mean (SD)                                                                                         
   Mobility                                                                       22.5 (24.0)     40.8 (27.4)     \<**0.001**
   ADL                                                                            23.9 (23.9)     32.0 (28.4)     0.066
   Emotional well-being                                                           23.5 (21.7)     39.4 (24.4)     \<**0.001**
   Stigma                                                                         21.2 (25.1)     23.5 (25.7)     0.609
   Social support                                                                 7.5 (15.9)      20.1 (25.9)     \<**0.001**
   Cognition                                                                      16.6 (20.0)     20.7 (20.3)     0.243
   Communication                                                                  13.4 (18.4)     18.9 (21.5)     0.105
   Bodily discomfort                                                              17.2 (20.1)     33.0 (25.3)     \<**0.001**
   PDSI                                                                           17.9 (14.2)     28.3 (15.7)     \<**0.001**

**Notes:**

Score A is the sum of UPDRS -- Part III items concerning facial expression, tremor, rigidity and bradykinesia, which are considered relatively [l]{.smallcaps}-dopa responsive.

Score B is the sum of UPDRS -- Part III items concerning speech and axial impairment (arising from chair, posture, postural stability and gait), which are considered relatively [l]{.smallcaps}-dopa nonresponsive.

Calculated via diving current UPDRS score by duration of PD. Univariate comparisons have been performed using either independent samples *t*-test, chi-square test or Fisher's exact test, wherever appropriate. Statistically significant *P*-values (*P*\<0.05) are presented in bold.

**Abbreviations:** QoL, quality of life; PD, Parkinson's disease; SD, standard deviation; IHD, interstitial heart disease; TIA, transient ischemic attack; UPDRS, Unified Parkinson's Disease Rating Scale; ADL, activities of daily living; H&Y, Hoehn and Yahr; PIGD, postural instability--gait difficulty; FOSS, freezing--speech--swallowing; HADS, Hospital Anxiety and Depression Scale; FSS, Fatigue Severity Scale; MNA, Mini-Nutritional Assessment; SCOPA-PS, Scales for Outcomes in Parkinson's Disease -- Psychosocial; PDQ-39, 39-item PD Questionnaire; PDSI, Parkinson's Disease Summary Index.
